Filing Flows › ResMed (RMD) › Q4 FY25
ResMed (RMD) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Aug 8, 2025
ResMed (RMD) reported revenue of $1.3B for the fourth quarter fiscal 2025 (Q4 FY25), +10% from a year earlier and +4% from the quarter before. Operating margin was 33.7%, net earnings $380M (28.2% of revenue).
ResMed, Q4 FY25: revenue $1.3B (+10% year over year), operating margin 33.7%, net earnings $380M, operating cash flow $539M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3B | +4% | +10% |
| Gross profit | $820M | +7% | +15% |
| Operating profit | $455M | +7% | +19% |
| Net earnings | $380M | +4% | +30% |
| Operating cash flow | $539M | -7% | +22% |
| Free cash flow | $508M | -9% | +22% |
What changed
Revenue was $1.3B in Q4 FY25, up 10% year over year and up 4% from the previous quarter. Sleep and Breathing Health was the largest line at 88% of revenue.
Gross margin was 60.8%, up 2.3 points from a year earlier. Operating profit was $0.45B, a 33.7% margin (up 2.6 points year over year). Of the extra revenue versus a year earlier, 59% reached operating profit, above the 31% margin then. Operating expenses grew 9% against revenue growth of 10%. The fastest-growing cost line was SG&A (+10%). Net earnings were $0.38B, up 30% year over year. The effective tax rate was 17.1%.
Operating cash flow was $0.54B (up 22% year over year), 142% of net earnings. Non-cash charges added back $0.06B of depreciation and amortization and $0.02B of share-based compensation. Working capital and other items added $0.07B. Capital expenditures of $0.03B left free cash flow of $0.51B.
Questions
What was ResMed's revenue in the fourth quarter fiscal 2025?
ResMed (RMD) reported revenue of $1.3B for the fourth quarter fiscal 2025 (Q4 FY25), +10% from a year earlier and +4% from the quarter before.
Was ResMed profitable in the fourth quarter fiscal 2025?
Operating profit was $455M (33.7% of revenue) and net earnings $380M.
Source: ResMed 10-K on SEC EDGAR.